Chimerix, Inc. (CMRX) Looks To Rally Up $60 Million Partly To Pay For Drug Trial With Josh Hardy
5/20/2014 8:57:44 AM
In part to fund a drug trial initiated because of public pressure, Durham’s Chimerix will sell 6.2 million shares in hopes of raising at least $60 million. In filings made after the stock market closed Monday, Chimerix (Nasdaq: CMRX) announced it would sell the additional shares in part to fund a clinical trial to test its lead drug candidate, brincidofovir, on treating an adenovirus infection. Chimerix had focused its development of brincidofovir on treating double-stranded DNA (dsDNA) viral infections, including cytomegalovirus and adenovirus, that are common in transplant patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by